Table 1

Trial characteristics of the analytic dataset

AuthorsNSexMean age (SD)Assessments available for linkage by visitTrial inclusion criteria
Rogers and Friedhoff29 156Male: 63
Female: 93
71.9 (7.4)ADAS-Cog, MMSE
0, 1, 3, 6, 9, 12
MMSE: 10–26
CDR: 1 or 2
Rogers et al 23 481Male: 176
Female: 305
74.0 (7.6)ADAS-Cog, MMSE
0, 3, 6, 9, 12
MMSE: 10–26
CDR: 1 or 2
Rogers et al 30 473Male: 180
Female: 293
73.5 (7.2)ADAS-Cog, MMSE
0, 6, 12, 18, 24
MMSE: 10–26
CDR: 1 or 2
Black et al 16 342Male: 101
Female: 241
78.1 (7.6)MMSE: 0 to 24
SIB: −1, 8, 16, 24
MMSE: 1–12
Modified Hachinski Ischemic Score: 6 or less
Functional Assessment Staging: 6 or more
Farlow et al 24 1444Male: 539
Female: 905
74.2 (7.9)MMSE, SIB
0, 6, 12, 18, 24
MMSE: 0–20
SIB: 90 or less
Cornell Scale for Depression in Dementia score: under 12
  • Week −1 refers to the screening assessment that was 28±7 before the drug administration (mean 23.67 days).

  • ADAS-Cog, Alzheimer’s Disease Assessment Scale–Cognitive Subscale; CDR, Clinical Dementia Rating; MMSE, Mini-mental State Examination; SIB, Severe Impairment Battery.